// App-Quantinova.ai

3066 : A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.

Researchers

Presenter

  • Jayesh Desai

Principal Investigators

  • Ben Markman

  • Shahneen Kaur Sandhu

  • Hui Kong Gan

  • Michael Friedlander

  • Ben Tran

  • Tarek Meniawy

  • Vishal Boolell

  • Duncan Colyer

  • Christie Norris

  • Malaka Ameratunga

  • Jason Yang

  • Kang Li

  • Lai Wang

  • Lusong Luo

  • Zhen Qin

  • Michael Millward

Medical Centers

  • Royal Melbourne Hospital, Melbourne, Australia

  • Monash Medical Centre, Melbourne, Australia

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Austin Health and Olivia Newton-John Cancer Research Institute, Melbourne, Australia

  • Prince of Wales Hospital, Randwick, Australia

  • Linear Clinical Research/Sir Charles Gairdner Hospital, Nedlands, Australia

  • BeiGene (Beijing) Co., Ltd., Beijing, China

Locations

  • China

  • Australia

Companies

  • BeiGene (Beijing) Co

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

Drug/Treatment

  • Tislelizumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Multicenteric

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT02407990

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved